Dr. Thomas A. Wolf, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 547
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Nebraska College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NE license 23824 -
Hospitalist Physician
KS license 0430314
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Methodist Hospital Omaha, NE
- Methodist Fremont Health Fremont, NE
Medical groups
- Physicians Clinic Inc (561 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 547
- Services billed
- 13,257
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 1,620 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,395 | 469 |
| Insertion of needle into vein for collection of blood sample | 738 | 423 |
| Hemoglobin a1c level | 403 | 210 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 395 | 339 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 330 | 78 |
| Manual urinalysis test with examination using microscope, automated | 193 | 180 |
| Administration of influenza virus vaccine | 165 | 162 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 161 | 158 |
| Automated urinalysis test | 130 | 126 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 46 payments worth $781 in total to this clinician.
| Lilly USA, LLC | $126 |
|---|---|
| Novo Nordisk Inc | $112 |
| AbbVie Inc. | $75.80 |
| Mannkind Corporation | $65.14 |
| AstraZeneca Pharmaceuticals LP | $61.96 |
| Pfizer Inc. | $54.71 |
| Vertex Pharmaceuticals Incorporated | $35.57 |
| Amgen Inc. | $31.49 |
| Food and Beverage | $739 |
|---|---|
| Education | $42.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Dec 19, 2025 | Education AFREZZA · DIABETES MEDICINE · in-kind | $42.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 7 companies. The companies reported $511,367 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc. · Completed · NCT05827978 - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.